Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Laboratory of Intestinal Adaptation and Recovery, Bnai Zion Medical Center, Haifa, Israel.
JPEN J Parenter Enteral Nutr. 2010 Sep-Oct;34(5):503-12. doi: 10.1177/0148607110362586.
The purpose of the present study was to evaluate the effects of ω-3 fatty acids (Omegaven) on early intestinal adaptation in rats with short bowel syndrome (SBS).
Male Sprague-Dawley rats were randomly assigned to 1 of 4 groups: sham rats underwent bowel transection; SBS rats underwent 75% bowel resection; SBS-O ω-3 rats underwent bowel resection and were treated with oral Omegaven given by gavage; and SBS-I ω-3 rats underwent bowel resection and were treated with Omegaven given intraperitoneally. Rats were killed on day 14. Parameters of intestinal adaptation (bowel and mucosal weight, mucosal DNA and protein, villus height and crypt depths, cell proliferation and apoptosis) were determined at time of death. Real-time polymerase chain reaction was used to determine the level of Bax and Bcl-2 messenger RNA (mRNA). Statistical analysis was performed using Kruskal-Wallis test followed by post hoc test, with P < .05 considered statistically significant.
Oral ω-3 supplementation did not significantly change intestinal regrowth. In contrast, parenteral ω-3 in rats that underwent resection resulted in higher bowel and mucosal weights, mucosal DNA and protein in ileum, villus height in ileum, crypt depth in jejunum and ileum, and greater rates of cell proliferation in jejunum and ileum compared with SBS animals. The initial decreased levels of apoptosis corresponded with the early decrease in Bax and increase in Bcl-2 mRNA levels.
Parenteral but not enteral Omegaven augments and accelerates structural bowel adaptation in a rat model of SBS. Increased cell proliferation and decreased apoptosis reflect increased cell turnover in Omegaven-treated animals.
本研究旨在评估 ω-3 脂肪酸（欧米加威）对短肠综合征（SBS）大鼠早期肠道适应的影响。
雄性 Sprague-Dawley 大鼠随机分为 4 组：假手术组大鼠行肠横断术；SBS 组大鼠行 75%肠切除术；SBS-Oω-3 组大鼠行肠切除术并经灌胃给予口服欧米加威治疗；SBS-Iω-3 组大鼠行肠切除术并经腹腔内给予欧米加威治疗。大鼠于第 14 天处死。死亡时测定肠道适应参数（肠和黏膜重量、黏膜 DNA 和蛋白质、绒毛高度和隐窝深度、细胞增殖和凋亡）。采用实时聚合酶链反应测定 Bax 和 Bcl-2 信使 RNA（mRNA）水平。采用 Kruskal-Wallis 检验后行 post hoc 检验进行统计学分析，P<0.05 为差异有统计学意义。
口服 ω-3 补充剂并未显著改变肠道再生。相反，接受切除术的大鼠给予肠外 ω-3 治疗可导致回肠的肠和黏膜重量、黏膜 DNA 和蛋白质增加，绒毛高度增加，空肠和回肠隐窝深度增加，以及空肠和回肠细胞增殖率增加。初始的凋亡水平降低与 Bax 早期降低和 Bcl-2 mRNA 水平升高相对应。
肠外而非肠内给予欧米加威可增强并加速 SBS 大鼠的结构性肠道适应。细胞增殖增加和凋亡减少反映了欧米加威治疗动物的细胞周转率增加。
